Physician profile
Sandeep Devarapalli
NPI 1356756142
$1,170.69
in general payments reported to CMS, 2019-2025
23 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $36.68 · 2021: $43.43 · 2022: $16.58 · 2023: $126 · 2024: $87.66 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $244.16 | 2020-2025 | Rystiggo, Zilbrysq, Briviact |
| Neurelis, INC. | $174.17 | 2024-2025 | Valtoco |
| Amgen INC. | $78.37 | 2019-2025 | Uplizna |
| Abbvie INC. | $70.01 | 2023-2025 | Botox, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $67.36 | 2019-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $66.23 | 2024-2025 | Amvuttra |
| Argenx US, INC. | $52.78 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $48.77 | 2025 | Symbravo |
| Csl Behring | $44.80 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $31.25 | 2019 | |
| Sk Life Science, INC. | $30.64 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $30.57 | 2025 | |
| Lundbeck LLC | $27.38 | 2025 | Vyepti |
| Biogen, INC. | $25.92 | 2025 | Skyclarys |
| Genzyme Corporation | $25.69 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.97 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.72 | 2025 | Keveyis |
| Kyowa Kirin, INC. | $21.50 | 2023 | Nourianz |
| Janssen Biotech, INC. | $21.29 | 2024 | Rybrevant |
| Lilly USA, LLC | $18.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2025 | Hyqvia |
| Merz North America, INC. | $15.16 | 2019 | |
| Eisai INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Devarapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.